TITLE

Use and Limitations of Varicella-Zoster Virus—Specific Serological Testing to Evaluate Breakthrough Disease in Vaccinees and to Screen for Susceptibility to Varicella

AUTHOR(S)
Breuer, Judith; Schmid, D. Scott; Gershon, Anne A.
PUB. DATE
March 2008
SOURCE
Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS147
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A plethora of tests for determining the presence of antibodies to varicella-zoster virus (VZV) have been developed over the years, with a wide range of performance standards. There is general agreement that the presence of VZV antibodies in serum indicates immunity to varicella and protection from chickenpox, although the role of specific antibody in mediating protection remains unclear. Both antibodies and cellular immunity probably interact to mediate immunity to the virus. In any case, VZV-specific serum antibody is a useful indicator of protection against chickenpox in patients and persons at high risk of exposure, whether they have been immunized or naturally infected. Serological tests are also a useful implement for evaluating the length of time that immunity to varicella persists after vaccination and whether waning of vaccine-induced immunity occurs. The purpose of this review is to contrast the strengths and weaknesses of currently available VZV antibody assays. Although several of these methods are useful for various specific applications, simpler and more accurate tests to measure antibodies to VZV are a high priority for future research and development.
ACCESSION #
31645386

 

Related Articles

  • Humoral and Cell-Mediated Immune Responses in Children and Adults after 1 and 2 Doses of Varicella Vaccine. Watson, Barbara // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS143 

    Humoral and cell-mediated immune responses to varicella-zoster virus (VZV) have been evaluated after 1 and 2 doses of live attenuated varicella vaccine, Oka strain, in several studies. One dose of varicella vaccine, however, elicits detectable immune responses that are low and, in some cases,...

  • Perspective on Live Varicella Vaccine. Gershon, Anne A.; Katz, Samuel L. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS242 

    The attenuation of varicella-zoster virus (VZV) by Takahashi in 1974 was a remarkable achievement. It swiftly led to development of a live vaccine against chickenpox, which was initially tested in Japan. With its successful employment in immunocompromised children to prevent morbidity and...

  • Development of Varicella Vaccine. Takahashi, Michiaki; Asano, Yoshizo; Kamiya, Hitoshi; Baba, Koichi; Ozaki, Takao; Otsuka, Terumasa; Yamanishi, Koichi // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS41 

    The Oka strain of varicella-zoster virus (VZV) was first isolated from vesicles of an otherwise healthy 3-year- old boy with typical varicella. The virus was passaged 11 times in human embryonic lung fibroblasts at 34°C and 12 times in guinea pig embryo fibroblasts (GPEFs) at 37°C. GPEFs...

  • Varicella Immunogenicity with 1- and 2-Dose Regimens of Measles-Mumps-Rubella-Varicella Vaccine. Shinefield, Henry R.; Black, Steve; Kuter, Barbara J. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS152 

    A quadrivalent vaccine combining measles, mumps, rubella, and varicella antigens (MMRV) was developed to increase the coverage of varicella vaccine and reduce the number of injections children receive. Although the varicella antigen is as immunogenic in the latest formulation of MMRV vaccine as...

  • An Economic Analysis of the Universal Varicella Vaccination Program in the United States. Fangjun Zhou; Ortega-Sanchez, Ismael R.; Guris, Dalya; Shefer, Abigail; Lieu, Tracy; Seward, Jane F. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS156 

    Frequent varicella outbreaks with sizable impact on the US public health system have continued to occur despite the success of the country's 1-dose varicella vaccination program. The Advisory Committee on Immunization Practices recently recommended adding a routine second dose of varicella...

  • Vaccine Oh Variants and Sequence Variability in Vaccine-Related Skin Lesions. Breuer, Judith; Scott Schmid, D. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS54 

    As with most live attenuated viral vaccines, varicella vaccine comprises a mixture of variant strains. Knowledge about the pathogenic potential of individual strains in the varicella vaccine is limited. Vaccination against chickenpox causes a usually modified varicella-like rash in a small...

  • Lack of Association between Age at Varicella Vaccination and Risk of Breakthrough Varicella, within the Northern California Kaiser Permanente Medical Care Program. Black, Steve; Ray, Paula; Shinefield, Henry; Saddler, Patricia; Nikas, Alexander // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS139 

    Background. Varicella vaccine currently is recommended for children between 12 and 18 months of age. However, rates of breakthrough varicella have been reported to be higher among children vaccinated before 14 or 15 months of age and to increase with time since vaccination. Methods. An ongoing...

  • Varicella Vaccine Effectiveness in the US Vaccination Program: A Review. Seward, Jane F.; Mann, Mona; Vázquez, Marietta // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS82 

    Varicella vaccine (Varivax, Merck) has been available in the United States since 1995. We reviewed published results of postlicensure studies of vaccine effectiveness. Among 19 studies, 17 reported on the effectiveness of vaccine received before exposure, and 2 reported on effectiveness after...

  • Varicella Vaccination of Immunocompromised Children. Levin, Myron J. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS200 

    Background. Exposure of immunocompromised children to varicella often requires postexposure prophylaxis. Exposures requiring this management are often not recognized. Varicella can he a severe disease when it occurs in immunocompromised children, in spite of antiviral therapy. Varicella exposure...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics